ArticleScientific reports2026
Automated OCT-tailored and same-visit biomarker-targeted microperimetry in geographic atrophy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal Prediction of Retinal Sensitivity Based on Disease Progression Quantified From Optical Coherence Tomography in Geographic Atrophy.Investigative ophthalmology & visual science · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This proof-of-concept study developed and validated an automated, biomarker-targeted, real-time microperimetry (MP) approach for individualized structure-function assessment in geographic atrophy (GA). Patients underwent volumetric spectral-domain optical coherence tomography (OCT) and mesopic MP. Automated deep learning-based OCT segmentation using a clinically validated software was applied to identify regions of ellipsoid zone loss (EZL) and retinal pigment epithelium loss (RPEL). A rule-based algorithm then selected 40 biomarker-targeted retinal test locations, with test-point density dynamically adapted to individual lesion morphology and deliberately prioritized within EZL rather than uniformly distributed. Statistical analysis employed multivariable mixed-effects models. In 64 eyes from 44 patients (mean age 79.1 ± 5.0 years; 59% female), 2,560 targeted MP stimuli were tested. Mean retinal sensitivity (RS) was 7.2 ± 7.4 dB in RPEL, 13.3 ± 7.1 dB in EZL, and 19.0 ± 5.0 dB in preserved retina (p < 0.001). The median deviation between intended and actual test locations was 38.2 μm (IQR 24.6–59.3 μm), with 98.5% of points correctly localized. This OCT-based, biomarker-guided MP approach enables precise, patient-specific structure-function mapping within a single visit and may serve as a sensitive functional endpoint in future GA trials and clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.